<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360915</url>
  </required_header>
  <id_info>
    <org_study_id>ASK-LC-120067-Ib</org_study_id>
    <nct_id>NCT04360915</nct_id>
  </id_info>
  <brief_title>Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects</brief_title>
  <official_title>Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic characteristics of ASK120067 and CCB4580030 after the single
      oral administration of ASK120067 in fast and after a high-fat meal in healthy Chinese
      subjects, and to evaluate the effect of food on the bioavailability of ASK120067.To evaluate
      the safety of ASK120067 tablets administered orally in fast and fed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out area under the plasma concentration-time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out time to reach maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent end elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Î»z</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)</time_frame>
    <description>Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events</measure>
    <time_frame>Adverse events will be collected from baseline until 12 days after the administration and the follow-up period</time_frame>
    <description>Assessed by number and severity of adverse events as recorded on the case report form.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Locally Advanced or Metastatic NSCLC</condition>
  <arm_group>
    <arm_group_label>ASK120067 in fast condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take ASK120067 tablets orally once in the first day at 160mg in fast condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASK120067 in fed condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take ASK120067 tablets orally once in the first day at 160mg in fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASK120067</intervention_name>
    <description>Take ASK120067 tablets orally in first day at 160 mg in fast condition.</description>
    <arm_group_label>ASK120067 in fast condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ASK120067 in fed condition</intervention_name>
    <description>Take ASK120067 tablets orally in first day at 160 mg in fed condition.</description>
    <arm_group_label>ASK120067 in fed condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Healthy subjects aged 18 or above and 45 or below, male and female;

          -  2) The weight of male subjects shall not be less than 50 kg, and that of female
             subjects shall not be less than 45 kg.Body mass index (BMI) = weight (kg)/height2
             (m2), BMI = Within the range of 19.0~26.0 (including the critical value);

          -  3) Normal or abnormal physical examination (physical examination, vital signs,
             laboratory examination, 12-lead electrocardiogram, frontal and lateral chest
             radiographs, etc.) during the screening period has no clinical significance;

          -  4) Subjects (including male subjects) are willing to have no pregnancy plan from the
             screening date to 6 months after the last dose, and are willing to take effective
             contraceptive measures;

          -  5) Subjects should sign the informed consent before the test, fully understand the
             test content, process and possible adverse reactions, have good communication with
             researchers and complete the test according to the test plan.

        Exclusion Criteria:

          -  1) patients with clinical significance who are abnormal by comprehensive physical
             examination, vital signs examination, routine laboratory examination (blood routine,
             urine routine, blood biochemistry, coagulation function), 12-lead electrocardiogram,
             and positive and lateral chest radiographs;

          -  2) HBSAg HCVAb HIVAb, treponema palliatum antibody and other test results were
             positive;

          -  3) QTc interphase abnormality (QTc&gt;450ms) with clinical significance;

          -  4) participated in the drug clinical trial within 3 months before the trial;

          -  5) taking any medication 14 days before the trial;

          -  6) surgical resection history, such as: hepatectomy, nephrectomy, digestive organ
             (gallbladder) resection;

          -  7) history of tuberculosis;

          -  8) past history of deep vein thrombosis/other thromboembolic events, abnormal
             coagulation factors, thrombocytopenia, or abnormal platelet function;

          -  9) previous history of interstitial lung disease (ILD), drug-induced ILD, radioactive
             pneumonia requiring steroid treatment, or clinically active ILD with evidence;

          -  10) allergic or hypersensitive to ASK120067 experimental active ingredients or
             inactive excipients, drugs with similar chemical structure to the experimental drugs
             or drugs with the same target, allergic to two or more drugs and food;

          -  11) there are swallowing difficulties or gastrointestinal diseases affecting drug
             absorption;

          -  12) have any disease that increases the risk of bleeding, such as acute gastritis or
             gastric and duodenal ulcers;

          -  13) habitual constipation or diarrhea;

          -  14) heavy drinking and/or a history of excessive drinking (14 units of alcohol per
             week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);

          -  15) alcohol breath test &gt; 0.0mg /100mL;

          -  16) drug abuse screening positive;

          -  17) smoking history, smoking more than 5 cigarettes per day in the first 3 months of
             the screening period or habitual use of nicotine-containing products, and unable to
             quit during the trial;

          -  18) those with positive urine nicotine detection results at the screening stage;

          -  19) having a history of blood or needle sickness;

          -  20) habitual consumption and consumption of special diet (including grapefruit juice,
             star fruit, pitaya fruit, etc.) within 7 days before the test, or the presence of
             other factors affecting drug absorption, distribution, metabolism, excretion, etc.;

          -  21) blood donation or massive blood loss (&gt; 400 mL) within 3 months prior to the
             trial;

          -  22) an acute illness or accident occurs during the screening period;

          -  23) the female subjects were lactating, or the pregnancy test results were positive,
             or they had unprotected sex within 2 weeks before the screening date;

          -  24) there are other conditions that the researcher thinks are not suitable for
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zourong Ruan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

